Genzyme Sets Sights On 13 Drug Approvals By 2012; Only 2 Are NMEs
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Only two new molecular entities are included in Genzyme's plan for 13 drug approvals between now and 2012, CEO Henri Termeer said during the company's annual analyst and investor day May 7